Pfizer (PFE)
24.30
-0.36 (-1.46%)
NYSE · Last Trade: Nov 4th, 6:15 PM EST
Detailed Quote
| Previous Close | 24.66 |
|---|---|
| Open | 24.39 |
| Bid | 24.34 |
| Ask | 24.35 |
| Day's Range | 24.20 - 25.20 |
| 52 Week Range | 20.92 - 28.14 |
| Volume | 166,015,442 |
| Market Cap | 136.24B |
| PE Ratio (TTM) | 12.93 |
| EPS (TTM) | 1.9 |
| Dividend & Yield | 1.720 (7.08%) |
| 1 Month Average Volume | 59,976,964 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
As of November 4, 2025, the global financial markets are witnessing a significant shift, with a rallying US dollar and a retreating stock market exerting considerable downward pressure on gold and silver prices. This confluence of macroeconomic factors, primarily driven by a hawkish outlook on interest rates, is creating a
Via MarketMinute · November 4, 2025
Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk.
Via Benzinga · November 4, 2025
Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight.
Via Benzinga · November 4, 2025
Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Risestocktwits.com
Via Stocktwits · November 4, 2025
Stay informed about the most active stocks in the S&P500 index on Tuesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · November 4, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.
Via Chartmill · November 4, 2025
Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to Goldman Sachs.
Via Benzinga · November 4, 2025
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Tuesday's session.
Via Chartmill · November 4, 2025
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date rallies.
Via Benzinga · November 4, 2025
Pfizer (PFE) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 4, 2025
Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid.
Via Investor's Business Daily · November 4, 2025
Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior.
Via Stocktwits · November 4, 2025
Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.87 per share was 37% above analysts’ consensus estimates.
Via StockStory · November 4, 2025
Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales.
Via Benzinga · November 4, 2025
Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.
Via The Motley Fool · November 4, 2025
Animal health company Zoetis (NYSE:ZTS) met Wall Streets revenue expectations in Q3 CY2025, but sales were flat year on year at $2.4 billion. On the other hand, the company’s full-year revenue guidance of $9.44 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.70 per share was 4.8% above analysts’ consensus estimates.
Via StockStory · November 4, 2025
Pfizer beat third-quarter expectations Tuesday, though both sales and profit fell year over year. The company also hiked its profit view.
Via Investor's Business Daily · November 4, 2025
Pfizer Q3 2025 earnings beat estimates and the company raised its full-year profit guidance, highlighting strong cost management and non-COVID portfolio growth.
Via Chartmill · November 4, 2025
The company noted that it is on track to deliver about $7.2 billion in overall anticipated net cost savings by the end of 2027.
Via Stocktwits · November 4, 2025
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS.
By Pfizer Inc. · Via Business Wire · November 4, 2025
Pfizer reported Q3 2025 revenue of $16.7 billion and adjusted EPS of $0.87, beating expectations and prompting a full-year EPS guidance raise.
Via Talk Markets · November 4, 2025
With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies.
Via The Motley Fool · November 4, 2025